Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/084539A METHOD FOR DETERMINING BACTERIAL SUSCEPTIBILITY TO ANTIBIOTICS
WO 06.05.2021
Int.Class C12Q 1/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Appl.No PCT/IL2020/051129 Applicant THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR) Inventor ALONI-GRINSTEIN, Ronit
The invention concerns methods for determining antimicrobial susceptibility of a microorganism (e.g. bacteria, fungi), comprising incubating a biological or environmental sample on a solid growth substrate containing at least one antimicrobial agent at varying concentrations for a relatively short period of time; recovering the microorganism growing on the solid growth substrate surface; and determining the microorganism quantity using a quantitative method, e.g. qPCR, and comparing the quantity to that of a sample grown on a solid substrate without antimicrobial agent. The method is particularly useful for Yersinia pestis, Bacillus anthracis and Francisella tularensis.
2.20210130443HIGH-AFFINITY MYCOBACTERIUM TUBERCULOSIS CAPSULE-SPECIFIC HUMAN MONOCLONAL ANTIBODY
US 06.05.2021
Int.Class C07K 16/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
Appl.No 17247532 Applicant Albert Einstein College of Medicine Inventor Jacqueline M. Achkar

Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.

3.20210132059IMMUNOASSAY DETECTION DEVICE WITH TEST STRIP ACCOMMODATED IN A CAPILLARY TUBE
US 06.05.2021
Int.Class G01N 33/558
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
558using diffusion or migration of antigen or antibody
Appl.No 17145197 Applicant GREAT NORTH RESEARCH AND INNOVATION LTD Inventor Georgios Gerardos

The present invention relates to a detection device for safe and convenient immunoassay of an analyte containing pathogens.

4.WO/2021/087388URINARY EV RNA BIOMARKERS FOR UROTHELIAL CANCER
WO 06.05.2021
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2020/058398 Applicant SHOWA DENKO MATERIALS (AMERICA), INC. Inventor MURAKAMI, Taku
Certain aspects of the present disclosure are generally directed to a minimally-invasive, or non-invasive, method that assesses a patient's condition with regard to urothelial cancer. Several embodiments of the present disclosure relate to methods to characterizing mRNA profiles of extracellular vesicles (EV) such as exosomes and microvesicles from urine samples of a patient to assess, diagnose, or otherwise determine that patient's status with regard to urothelial cancer.
5.20210132064BIOMARKERS FOR DETECTING MICROBIAL INFECTION
US 06.05.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 17052731 Applicant Roger Karlsson Inventor Roger Karlsson

The present invention provides specific peptide biomarkers and sets of peptide biomarkers for use in methods of detecting or identifying bacterial biomarkers in a sample, wherein said bacterial biomarkers can be used to detect Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and/or Moraxella catarrhalis in a sample. Kits and diagnostic methods are also provided.

6.WO/2021/085651ANTIBODY FOR DETECTING STAPHYLOCOCCUS AUREUS IN SAMPLE, METHOD FOR DETECTING STAPHYLOCOCCUS AUREUS USING SAID ANTIBODY, REAGENT, AND KIT
WO 06.05.2021
Int.Class C07K 16/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
Appl.No PCT/JP2020/041114 Applicant ASAHI KASEI KABUSHIKI KAISHA Inventor AIZAWA, Tomoyasu
Provided is an antibody capable of causing an antigen-antibody reaction with an epitope located in an C-terminal domain (CTD) of a ribosome protein L7/L12 in Staphylococcus aureus, wherein the C-terminal domain comprises amino acid residues located at position-55 to position-122, or a fragment of the antibody, or a derivative of the antibody or the fragment.
7.20210134395EARLY INFECTIOUS DISEASE SIGN DETECTION DEVICE, EARLY INFECTIOUS DISEASE SIGN DETECTION METHOD, AND RECORDING MEDIUM
US 06.05.2021
Int.Class G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Appl.No 17252973 Applicant NEC CORPORATION Inventor Masahiro HAYASHITANI

An early infectious disease sign detection device includes: an early infectious disease sign detection unit that generates early sign information indicating an early sign that a determination target patient is going to develop an infectious disease, by using learning data indicating a result of learning about biological information of a patient who has developed the infectious disease among a plurality of patients, and biological information acquired for the determination target patient; and an action information output unit that outputs action information for the infectious disease for the determination target patient, based on the early sign information.

8.20210132049Simultaneous Parallel Signal Amplification and Analyte-Ligand Capture Functions
US 06.05.2021
Int.Class G01N 33/545
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
544the carrier being organic
545Synthetic resin
Appl.No 16617374 Applicant George Mason University Inventor Lance A. Liotta

A device and system for conducting accurate diagnosis of states of disease or health, including cancer, with high sensitivity and specificity is described. The system employs a portable cassette-based testing system which is configured to detect pp analytes captured by hydrogel particles equipped with affinity bait(s) and an amplification reporter system. The affinity baits bind to a wide range of analytes, including: metabolites, proteins, nucleic acids, lipids, hormones, cytokines, growth factors, biomarkers, virus particles, exosomes, bacteria, fungi, drug compounds, synthetic organic compounds, volatile odorants, toxicants, and pollutants. The affinity baits bind with extremely high affinity, preserving the captured analyte. This system can increase the sensitivity of detection of said analytes up to ten-thousand-fold.

9.20210128644METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION
US 06.05.2021
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
Appl.No 17093154 Applicant Mayo Foundation for Medical Education and Research Inventor Purna C. Kashyap

This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

10.3815699NEW MEANS AND METHODS FOR THERAPY AND DIAGNOSIS OF ADENOVIRAL INFECTION
EP 05.05.2021
Int.Class A61K 33/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
36Arsenic; Compounds thereof
Appl.No 19205530 Applicant UNIV MUENCHEN TECH Inventor SCHREINER SABRINA
The present invention relates to the field of adenovirus infection, in particular to therapy and diagnosis of an adenovirus infection in a subject. Specifically, the present invention relates to the use of arsenic trioxide (As2O3) for treating or preventing an adenovirus infection in a subject. Furthermore, the present invention relates to a method of detecting an adenovirus infection based on detecting SUMOylation of adenoviral E2A protein in a patient sample.